Navigation Links
Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial
Date:5/10/2013

THE WOODLANDS, Texas, May 10, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial.  LX4211 is an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2).

The pioneer phase of the study was designed to gain important initial information regarding the safety of co-administration of LX4211 with insulin in this, the first test of dual inhibition of SGLT1 and SGLT2 in patients with insulin-dependent type 1 diabetes.  The successful conclusion of the 28-day pioneer group enables the initiation of the placebo-controlled expansion phase of the study to commence in up to 30 patients with type 1 diabetes.  Based on the results observed in the pioneer group, Lexicon has identified the 400 mg once daily dose of LX4211 as the appropriate treatment for the expansion phase of the trial.

"This is a very important first step in the future development of LX4211 in type 1 diabetes," said Dr. Arthur Sands , president and chief executive officer of Lexicon. "The preliminary results are very encouraging and provide a strong rationale for moving into the expansion phase of the trial."

LX4211, a first-in-class dual inhibitor, reduces the amount of glucose that enters the bloodstream from the gastrointestinal (GI) tract by inhibiting SGLT1, the major transporter responsible for glucose absorption, and enhances glucose excretion in the urine by inhibiting SGLT2, the major transporter responsible for glucose reabsorption by the kidney. Lexicon has previously demonstrated that SGLT1 inhibition by LX4211 incre
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014  Northstar Global Business Services, Inc. ... (DTC) has made their final decision and has ... Company,s stock effective December 15, 2014, and has ... depository and book entry transfer services. All deposit restrictions ... once again fully "DTC Eligible", and has resumed ...
(Date:12/17/2014)... 17, 2014 , ... a hub of information concerning the biopharmaceutical Group,s national and ... further addition to the recently launched institutional website that is ... been enriched by a new chapter in the fascinating story ... richly detailed and panoramic hub on the world of clinical ...
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
Breaking Medicine Technology:Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... IDAHO FALLS, Idaho, Dec. 12, 2011 International Isotopes ... a conference call to give an update of the ... performance of its core business segments as well as ... depleted uranium de-conversion project.What:  , International Isotopes Inc. General ...
... of Eli Lilly and Company (NYSE: LLY ) ... December 12, 2011. Baicker, 40, is Professor of Health Economics ... Harvard School of Public Health. She is also a research ... elected member of the Institute of Medicine. As a member of ...
Cached Medicine Technology:International Isotopes Inc. Announces Conference Call to Give an Update on the Company's General Business Status 2Katherine Baicker Elected to Lilly Board of Directors 2
(Date:12/19/2014)... It’s very easy to become overwhelmed with the ... to the wayside until Christmas and the New Year are ... and that burning desire to just escape it all and ... to Telluride with a no-fuss, affordable package. Montrose Days Inn ... resort, and ensure that all accommodations are met. Plus, everyone ...
(Date:12/19/2014)... Energy Textiles is excited to ... Celliant, the world’s leading responsive textile, can now ... There are a number of benefits to wearing ... and balanced body temperature; which can lead to ... enhanced athletic performance; and overall wellness. In addition, ...
(Date:12/19/2014)... 19, 2014 SuperCloset raises the bar ... SuperCloset continues to offer indoor growers the most efficient ... the new SuperClone Rooms with the award winning ... indoor hydroponic grow room setup. , The SuperClone Room ... SuperPonic SuperCloner 50 . The SuperClone ...
(Date:12/19/2014)... 2014 An evening dress is perfect for ... closet. Discount-Dress.com, a distinguished dresses retailer, has unveiled its new ... in this great shopping platform. Customers can view ... hard work, Discount-Dress.com has been accepted and praised by customers ... easier shopping stage for clients. In order to expand its ...
(Date:12/19/2014)... warns parents that buying an older car for their teens may ... drivers killed in the United States between 2008 and 2012 were ... lacked important safety features that are available on newer cars, the ... were in cars at least six years old, 34 percent were ... cars 11 to 15 years old, and 17 percent were in ...
Breaking Medicine News(10 mins):Health News:Days Inn Montrose Colorado Delivers Last Minute Holiday Season Ski Getaway Accommodations 2Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Older Cars a Bad Choice for Younger Drivers 2
... The Food Allergy &,Anaphylaxis Network (FAAN) will hold ... May 31, 2008. Many families struggle with,how best to ... living with food allergies for years or are dealing ... attendees will learn tips and strategies for living better,while ...
... potent cancer gene. , The gene, known as ERG, ... including leukemia and sarcoma. American scientists showed in 2005 that ... cancers. , It was unclear, however, what function ERG ... so carcinogenic when mutated. , The team at WEHI ...
... Assisted living communities save time and money accepting ... electronic payments direct from resident bank accounts, ... today that it,has added PaySimple, the leading provider ... its customers to help simplify resident billing,and collection ...
... 27 Health Fitness,Corporation (OTC Bulletin Board: HFIT), ... management solutions, today announced that,it has completed its ... plan, the company repurchased 1.14 million shares of ... with Securities and Exchange,Commission Rule 10b-18 and other ...
... to be poorer and without insurance , , TUESDAY, May 27 ... receive treatment, even though they have access to care, according ... funding from drug maker GlaxoSmithKline, was published in the May ... . , The research involved 97 Boston-area men with the ...
... The current recommended daily allowance (RDA) of vitamin D ... research reveals that children may need and can safely ... report in The Endocrine Societys Journal of Clinical Endocrinology ... bone health of children worldwide and may have other ...
Cached Medicine News:Health News:FAAN Brings 'Food Allergies: Living and Learning' to Annual Food Allergy Conference in New York 2Health News:FAAN Brings 'Food Allergies: Living and Learning' to Annual Food Allergy Conference in New York 3Health News:Vigilan Offers PaySimple to Simplify Resident Billing and Collection 2Health News:Health Fitness Completes Share Repurchase Plan 2Health News:Men With Low Testosterone Not Receiving Treatment 2Health News:Current vitamin D recommendations fraction of safe, perhaps essential levels for children 2
... path that allows users to take full ... potential to combine two units offers fully ... stimulating coil. The ability to change pulse ... level of each Magstim 200 allows for ...
... is a surgical approach to glaucoma management ... application. The ciliary body (which produces aqueous ... the anterior or posterior segment, through the ... are easily and accurately identified utilizing endoscopy. ...
... surgical approach to glaucoma management that employs ... ciliary body (which produces aqueous humour) is ... or posterior segment, through the endoscope in ... and accurately identified utilizing endoscopy. This allows ...
... of German Craftsmanship have produced ... the world. Ocutek® now makes ... holders of the coveted Meisterbrief ... apprenticeship, are qualified to become ...
Medicine Products: